Altevax SAS

MABDESIGN MEMBER

About us

Altevax is developing a first-in-class immunotherapy using melanin as an adjuvant. When linked to a disease-specific antigen using our technology, melanin helps trigger a strong, antigen-specific immune response of the CD8+ T cells.

Know-how

neuro oncology; clinical trials; in vivo models

Business offer

Glioblastoma immunotherapy & co-development or licensing for indications other than glioblastoma

Field of application
  • cellular immunotherapy
  • therapeutic vaccines
Therapeutic application
  • infectiology
  • immunology
  • oncology

Expertise

  • Target Selection & Validation
  • Gene / protein discovery
  • bioinformatics design
  • Assay development in in-vitro & in-vivo models
  • Immunotherapy Hit Discovery
  • Screening & Identification
  • In-vivo models
  • Immunotherapy Lead Generation
  • Epitope mapping
  • Pharmacology & Biological activity
  • PK/PD bioavailability
  • Mode of Action
  • Therapeutic efficacy
  • Safety
  • Specificity
  • Cell activation
  • Cell-based activation (APCs, AAPCs)
  • In-vivo activation (in human transgenic mouse models)
  • Immunotherapy Lead Optimization
  • Proof of concept
  • in-vivo models
  • Clinical Trials
  • Phase I
  • Phase II
  • Regulatory Filing
  • Regulatory Filing

Category

  • Therapeutic product

Contact